Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$126.91
-3.2%
$117.77
$65.67
$148.83
$11.09B0.871.55 million shs745,755 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$240.47
-0.4%
$238.98
$96.09
$260.19
$12.37B0.6771,757 shs277,126 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.04
+1.0%
$23.91
$13.39
$27.72
$12.48B1.685.31 million shs2.57 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.53
-0.3%
$13.46
$5.69
$13.60
$3.55B1.546.23 million shs3.03 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+1.10%-4.80%+33.25%+14.49%+91.20%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+0.80%+1.89%-0.18%+29.88%+127.09%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.47%-4.52%+6.76%+8.89%+65.03%
Organon & Co. stock logo
OGN
Organon & Co.
+0.30%+0.52%+0.93%+19.73%+34.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$126.91
-3.2%
$117.77
$65.67
$148.83
$11.09B0.871.55 million shs745,755 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$240.47
-0.4%
$238.98
$96.09
$260.19
$12.37B0.6771,757 shs277,126 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.04
+1.0%
$23.91
$13.39
$27.72
$12.48B1.685.31 million shs2.57 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.53
-0.3%
$13.46
$5.69
$13.60
$3.55B1.546.23 million shs3.03 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+1.10%-4.80%+33.25%+14.49%+91.20%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+0.80%+1.89%-0.18%+29.88%+127.09%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.47%-4.52%+6.76%+8.89%+65.03%
Organon & Co. stock logo
OGN
Organon & Co.
+0.30%+0.52%+0.93%+19.73%+34.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.80
Moderate Buy$156.5023.31% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.91
Moderate Buy$261.488.74% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.7314.74% Upside
Organon & Co. stock logo
OGN
Organon & Co.
1.71
Reduce$11.40-15.71% Downside

Current Analyst Ratings Breakdown

Latest OGN, ELAN, ABVX, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingOverweight$180.00
7/22/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Boost Price TargetEqual Weight$23.00 ➝ $26.00
7/20/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Initiated CoverageOutperform$310.00
7/20/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
DowngradeHoldStrong Sell
7/20/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UpgradeStrong-Buy
7/17/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingSell (D-)
7/17/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingSell (D-)
7/15/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
7/13/2026
Organon & Co. stock logo
OGN
Organon & Co.
UpgradeHold (C-)Hold (C)
7/9/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Boost Price TargetOverweight$165.00 ➝ $175.00
7/8/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingBuy$290.00
(Data available from 7/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M19.38N/AN/A$1.75 per share137.41
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.65$2.29 per share10.92$13.18 per share1.90
Organon & Co. stock logo
OGN
Organon & Co.
$6.22B0.57$5.78 per share2.34$2.89 per share4.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/14/2026 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A59.23N/A-26.59%-267.16%-28.53%8/10/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A20.191.66-4.95%7.42%3.66%8/5/2026 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.9314.543.931.253.99%99.95%6.22%8/4/2026 (Estimated)

Latest OGN, ELAN, ABVX, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.8938N/AN/AN/A$220.94 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.28N/AN/AN/A$1.31 billionN/A
8/4/2026Q2 2026
Organon & Co. stock logo
OGN
Organon & Co.
$0.87N/AN/AN/A$1.57 billionN/A
5/22/2026Q1 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
4/30/2026Q1 2026
Organon & Co. stock logo
OGN
Organon & Co.
$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.59%N/A8.60%N/A

Latest OGN, ELAN, ABVX, and AXSM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.6%5/11/20265/11/20266/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.25
8.25
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.32
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Organon & Co. stock logo
OGN
Organon & Co.
9.47
1.97
1.42

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Organon & Co. stock logo
OGN
Organon & Co.
1.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6187.16 millionN/ANot Optionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.61 million258.36 millionNot Optionable

Recent News About These Companies

Organon & Co. Shareholders Clear Sun Pharma Merger Deal
Organon & Co.
Organon & Co: Great Odds, Small Prize, Big Penalty

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abivax stock logo

Abivax NASDAQ:ABVX

$126.91 -4.25 (-3.24%)
As of 03:39 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$240.47 -1.06 (-0.44%)
As of 03:39 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$25.04 +0.26 (+1.03%)
As of 03:39 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.52 -0.04 (-0.26%)
As of 03:39 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.